Navigation Links
Roche Introduces Program to Facilitate Corporate Pandemic Stockpiling of Tamiflu(R)
Date:6/26/2008

sses and multiple levels of government to make Tamiflu more available and accessible to those who may need it in a pandemic. Roche increased global production of Tamiflu more than 15- fold and created a complete supply chain on U.S. soil at the request of HHS. The company has donated more than 5 million treatment courses to the WHO for use as a rapid response at the site of a pandemic outbreak and for its regional stockpiles.

Roche has also sponsored a series of pandemic planning workshops for businesses around the country, creating a forum for multi-sector dialogue. Insights, information and practical tools have been compiled by Roche at http://www.pandemictoolkit.com.

Roche has taken extensive steps to ensure its own business continuity and continued manufacturing of Tamiflu and other life-saving medicines during a pandemic outbreak. Roche has provided Tamiflu to all its employees in the U.S. and globally, along with medical consultation and education about disease prevention and pandemic flu.

To date, Roche U.S. has received inquiries from more than 800 U.S.-based companies, large and small in a variety of industries, with Tamiflu orders from more than 300 companies, in quantities ranging from a few hundred to hundreds of thousands of treatment courses.

For more information, businesses may contact Roche via phone: Pandemic Planning Hotline 888-394-2838, or by e-mail: Nutley.TAMIFLU_Inquiry@Roche.com.

About Tamiflu

Tamiflu, co-developed by Gilead Sciences, Inc., based in Foster City, CA, is indicated for the treatment of uncomplicated influenza caused by viruses types A and B in patients one year and older who have had flu symptoms for no more than two days. Tamiflu is also indicated for the prevention of influenza in patients one year and older. Tamiflu is not a substitute for annual early vaccination as recommended by the CDC.

Tamiflu was approved based on
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
2. Fontus Pharmaceuticals Acquires Nephrology and Endocrinology Drug from Roche Laboratories Inc.
3. Roche Signs Exclusive Distribution Deal with DxS for K-RAS and EGFR Cancer Mutation Tests
4. Two Roche Women Honored as 2008 Tribute to Women and INdustry Awardees
5. Roche Research Director Grace Ju Hailed as NJABR Outstanding Woman of Science
6. MacroChem Acquires Virium Pharmaceuticals
7. Rochester Medical Announces Second Quarter 2008 Earnings Conference Call April 29, 2008
8. Roche Molecular Diagnostics Invests $57.5 Million in Green Research Building
9. MacroChem Appoints David P. Luci as New CFO
10. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
11. Roche to Acquire Ventana for $89.50 per share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... DIEGO , Feb. 27, 2015  Pfenex Inc. ... the development of biosimilar therapeutics, today announced that it ... Francisco Marriott Marquis on March 2 nd at ... participate on a panel discussing the current state of ... of Biosimilars . For more information ...
(Date:2/26/2015)... -- S&P Capital IQ (MHFI) announced today that it ... Therapeutics Holdings Inc . MabVax Therapeutics ... focused on the development of vaccine and antibody-based therapies ... cancer. MabVax has discovered a pipeline of human monoclonal ... by patients who have been immunized against targeted cancers. ...
(Date:2/26/2015)... 26, 2015   Regulus Therapeutics Inc . (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, today ... and Chief Executive Officer of Regulus, will present a ... Annual Healthcare Conference on Wednesday, March 4, 2015 ... at the Boston Marriott Copley Place.  ...
(Date:2/26/2015)...  NuGene International, Inc. ("NuGene") (OTCQB: NUGN), the ... hair rejuvenation, has announced that it has selected ... investor relations and strategic communications. ... diversification strategies – and we need to communicate ... Ali Kharazmi CEO of NuGene when announcing this ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3
... a $500,000 start-up grant for the recently announced ... classified, defense-related projects. , ,The consortium, led ... include the UW System, the Medical College of ... Milwaukee School of Engineering. , ,The consortium will ...
... Inc., a Wisconsin company specializing in functional Magnetic ... nomination for the 2005 edition of the Minnies, ... for radiologists and related professionals in medical imaging. ... in 12 categories. AuntMinnie.com members voted Neurognostics one ...
... one of a two part article. The next installment covering ... week. , , You or your company may ... with patent matters. However, there is a growing group of entities ... of revenue. As a consequence, more and more businesses have to ...
Cached Biology Technology:Wisconsin consortium aims for defense business 2Patent enforcement: What you don't know might hurt you 2Patent enforcement: What you don't know might hurt you 3Patent enforcement: What you don't know might hurt you 4
(Date:2/5/2015)... TRIANGLE PARK, North Carolina , 5. ... sein 35. Jahr als spezialisiertes Logistikunternehmen und ... Position als einzige klinische Logistikfirma (Clinical Logistics ... Die Kernbotschaft der neuen Kampagne lautet ... und Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... 2015   Epic Sciences , a precision diagnostics company ... Murali Prahalad , Ph.D., president and CEO, is scheduled ... (PMWC) 2015: Silicon Valley, which is taking place at the ... on January 26-28, 2015. Dr. Prahalad ... Biomarkers." Last year, Epic Sciences was a finalist in the ...
(Date:2/5/2015)... Jan. 27, 2015   Marvin Test ... deployed, innovative test solutions for military, aerospace, ... of its TS-323 GENASYS Test Platform ... (LMSSC). GENASYS is a high-performance PXI-based system ... applications that require performance functional testing. GENASYS ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... An electronic device designed to "zap" away migraine pain before ... millions of people who suffer from the debilitating disease. ... appears to be effective in eliminating the headache when administered ... led by the Ohio State University Medical Center neurology investigators, ...
... most powerful tools of biomedical science, University of Texas ... dramatic success in the battle against colorectal cancer. , ... known as "small interfering RNAs" to block the spread ... Small interfering RNAs (siRNAs), first described in 2001, are ...
... that causes African sleeping sickness, scientists at Johns Hopkins have ... component of fat and the outer layer of all cells. ... parasite and could lead to a target for designing new ... and kills 50,000 a year worldwide. , Results of the ...
Cached Biology News:Device effective in zapping the pain out of migraines 2RNA interference stops colon cancer spread in mice 2African parasite makes component of fat differently from all other organisms 2African parasite makes component of fat differently from all other organisms 3
Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
Jak3 Antibody Ship: Hot Store: -20 C...
14-3-3 tau Antibody Shipping Temperature: HOT Storage Temperature: -20C...
... for all tested applications). ... from within residues 500 to the C-terminus of ... is proprietary) (Peptide available as ... ID: 51043 Swiss Protein ...
Biology Products: